Nasal Foralumab Shows Positive Results in Alzheimer’s Disease Study
The Journal of Clinical Nuclear Medicine has published results from a study of Tiziana Life Sciences’ nasal Foralumab. The study tested the drug in patients with moderate Alzheimer’s disease. Researchers gave one patient daily doses of nasal Foralumab for 13 weeks. They followed this with a 13-week treatment-free period. The patient showed reduced brain inflammation […]